SIR2501 / Sironax - LARVOL DELTA

Company Milestones: Vitalon Announces Completion of Phase I Clinical Trial of SIR2501 [Google translation] (bydrug.pharmcube.com) - "Recently, SIR2501, a candidate drug for neurological diseases independently developed by Vitallon...successfully completed the Phase I clinical trial in healthy subjects. The trial is a randomized, double-blind, placebo-controlled, single and multiple dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SIR2501 in healthy subjects....The Vitalon team is excited about the results of the Phase I trial of SIR2501..."

Trial completion • CNS Disorders

Phase 1 Study to Investigate SIR2501 in Healthy Adult Participants (ANZCTR) - P1 | N=112 | Recruiting | Sponsor: Sironax Australia Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: May 2024

Enrollment open • Trial initiation date • CNS Disorders

Phase 1 Study to Investigate SIR2501 in Healthy Adult Participants (ANZCTR) - P1 | N=112 | Not yet recruiting | Sponsor: Sironax Australia Pty Ltd

New P1 trial • CNS Disorders